Canadian Radiotheranostics Leaders’ Summit 2024
Canadian Radiotheranostics Leaders’ Summit 2024
Canadian Radiotheranostics Leaders’ Summit 2024
in partnership with
AGENDA
Please note that this agenda is subject to change.
8:00 am
Registration & light breakfast
MaRS Concourse
9:00 am
MaRS Auditorium
9:15 am
James Scongack
Summary: Chair James Scongack shares CNIC’s vision of hope and highlights the importance of radiotheranostics to cancer care. The world is relying on Canada to help combat global health challenges as an international isotope leader.
MaRS Auditorium
9:25 am
Dr. Patrick Veit-Haibach (Session Chair), Dr. Johannes Czernin
Summary: This presentation will focus on prospective clinical trials in prostate cancer that led to successful New Drug Applications (NDAs) by the US Food and Drug Administration, and resulted in inclusion in the NCCN prostate cancer guidelines and reimbursement by the US Medicare system as well as ongoing phase 3 clinical trials that will position theranostics earlier in the course of prostate cancer will be presented. Finally, experiences from the recently opened large UCLA theranostics outpatient center, the role and importance of inter-disciplinary collaborations, developments in industry and academia aimed at improving supply of and access to theranostics, and the overall business case will be highlighted.
MaRS Auditorium
9:55 am
Dr. Jonathan Irish (Session Chair), Dr. Johannes Czernin, Dr. Mark Harfensteller, Dr. Ting-Yim Lee, Dr. Kate Vallis
Summary: Precision radiopharmaceuticals are making cancer treatments more accurate and effective, yielding promising outcomes for patients. During this session, a panel of industry experts will share insights from the field and offer perspectives on what the future holds for innovation in precision radiopharmaceuticals. Panelists will discuss important topics like discipline integration in the nuclear medicine field, personalized dosing on a large scale, supply chain opportunities, and more.
MaRS Auditorium
10:35 am
Coffee & networking
MaRS Concourse
10:55 am
Session Chair: Dr. Cara Ferreira
CANDU and isotope production
John Burta
Design of radiopharmaceuticals: From idea to first in man
Dr. Joseph Lau
Clinical production of radiopharmaceuticals
Dr. Mike Kovacs
MaRS Auditorium
11:55 am
Dr. Stephanie Lheureux (Session Chair), Dr. Gang Zheng
Summary: This session will explore how reserachers are exploring next-generation porphysome nanoparticles generated by porphyrin-lipid bilayers are broadening the purview of radiotheranostics.
MaRS Auditorium
12:25 pm
Lunch sponsored by AtomVie Global Radiopharma Inc.
MaRS Concourse
1:30 pm
The session will consist of five short presentations, designed to provide the audience with new, exciting information about isotope and radiopharmaceutical advances in Canada.
Session Chair: Dr. Luke Brzozowski
Canadian Medical Isotope Ecosystem: Development and commercialization
Kathryn Hayashi
Immunocompetent and humanized mouse tumour models for preclinical studies of radiotheranostics
Dr. Raymond Reilly
Artificial Intelligence and theranostics
Dr. Etienne Rousseau
Equipment advances that enable life-changing results
Dr. Patrick Veit-Haibach
Re-imagining medicine to improve patients’ lives
Sophia Kajla
MaRS Auditorium
3:10 pm
Lady Sawoszczyk (Session Chair), Dr. Tony Falco, Steve Mettler, Dr. Arjun Sahgal, Richard Wiens
Summary: Contemporary hospitals are faced with the challenge of adapting to the advent of new healthcare technologies and infrastructure that provide life-changing results for patients. Panelists will discuss exciting new advancements in medical technology and specialized nuclear medicine infrastructure in Canadian hospitals.
MaRS Auditorium
3:40 pm
Coffee & networking
MaRS Concourse
4:00 pm
Rachel Sumner (Session Chair), Dr. Travis Besanger, Ram Mullur, Dr. Karin Stephenson
Summary: Panelists discuss workforce development and skills training for future isotope and healthcare leaders, as well as innovative initiatives and partnerships between industry and academia to ensure the future workforce is equipped to advance isotope innovation and address new challenges in global health.
MaRS Auditorium
4:30 pm
Dr. Glenn Bauman (Session Chair), Dr. Philip Cohen, MP Pam Damoff, Dr. Deanna Langer, Rebecca Lo Bue, Dr. Maureen Trudeau
Summary: With the support of government representatives, healthcare workers, and leaders in public and private health, this fireside chat will explore the challenges of responsible and equitable patient access. Experts discuss strategies to improving widespread access to radiotheranostics across Canada and globally, including public, private, and philanthropic approaches in the advancing field of nuclear medicine.
MaRS Auditorium
8:00 am
Registration & light breakfast
MaRS Concourse
9:00 am
Kathryn Hayashi, Owen Roberts
MaRS Auditorium
9:10 am
Amy Gottschling (Session Chair), MP Pam Damoff, MPP Natalia Kusendova-Bashta
Summary: Highlighting the theme of “Current advances and future opportunities,” representatives from the Federal and Ontario government discuss the opportunities for Canada to leverage the capacity of its isotope supply chain and maximize its leadership on a global scale, shaped by the current regulatory landscape for medical isotopes and radiopharmaceuticals.
MaRS Auditorium
9:40 am
Dr. Lana Janes (Session Chair), Celine Landie, Dr. Joe McCann, Bruno Paquin, Owen Roberts
Summary: During a time of economic growth and opportunity, panelists discuss the development of radiopharmaceuticals in Canada from clinical trial, commercialization, and patient delivery, and address commercialization opportunities and challenges in the isotope industry. Experts discuss the primary challenges to accessing risk-adverse capital in Canada and how industry, clinicians, and researchers can build more intentional relationships to tailor commercialization efforts to meet the needs of emerging projects, tracers, and studies.
MaRS Auditorium
10:10 am
Dr. Marianne Koritzinsky (Session Chair), Dr. Ana Kiess
Summary: As radiotheranostics expand in clinic and research, we are faced with new challenges and opportunities. How do we escalate dose while mitigating risk of potential late effects? How do we consider micro-scale dosimetry, especially for alpha emitters? Is personalized dosimetry a real possibility? This talk will explore ongoing research and regulatory discussions in these areas, including relevance to both beta and alpha emitters. We will highlight the initiatives of an international workgroup exploring radiopharmaceutical therapy normal tissue effects in the clinic (RPT-TEC), as well as other collaborative efforts.
MaRS Auditorium
10:05 –
10:50 am
Students will be participating in a “Career opportunity coffee break” to meet with prominent national leaders in the Canadian isotope and healthcare industry, allowing them to engage directly with speakers and presenters. Any interested Summit attendee is invited to participate in the Speed Networking with students. Coffee and refreshments will be provided.
Click here for more information about the Summit student track.
Collaboration room CR2
10:40 am
Coffee & networking
MaRS Concourse
11:00 am
Peter D’Amico (Session Chair), Michael Lee-Chin
Summary: Join Michael Lee-Chin, prominent Canadian investor and visionary, as he unveils his proven 3 P Framework for Wealth Creation: Predict, Plan, and Persevere. In this insightful presentation, Michael will delve into the transformative potential of nuclear medicine, positioning it as the cornerstone of the next major investment trend.
Drawing from his extensive experience as a successful owner, operator and investor, Michael will outline the strategic importance of predicting demographic shifts, thorough planning, and unwavering perseverance in capitalizing on emerging opportunities in the nuclear sector. Michael will share why nuclear energy stands poised to revolutionize not only the energy landscape but also address one of humanity’s greatest challenges: cancer.
This talk promises to enlighten and inspire attendees to take action, offering invaluable insights into the lucrative prospects awaiting those who embrace the nuclear renaissance. Don’t miss this opportunity to Do Well, by Doing Good with Michael Lee-Chin as your guide.
MaRS Auditorium
11:20 am
Session Chair: Dr. Mary Jessel
Canadian neuroendocrine cancer patient partnerships in research
Jackie Herman
Summary: Representing the only Canadian charity that supports neuroendocrine cancer patients, Jackie will speak to the goals and objectives of the Canadian Neuroendocrine Tumour Society (CNETS) in their patient & caregiver driven research funding program and the resulting collaborations and partnerships with research institutions and medical societies.
The current landscape of radiotheranostics trials in Canada
Dr. Rebecca Wong provides an overview of the current state of clinical trials using radiotheranostics in Canada, and discusses the types of projects, agents, tracers, and studies of interest to clinicians and researchers.
Enhancing patient safety through Quality Assurance in radiopharmaceutical therapy
Stephen Nelli
Summary: This presentation will explore the development and implications of the Pan-Canadian Collaboration for Quality Radiopharmaceutical Therapy (PCQRT) document, a comprehensive guideline aiming to elevate the standards of quality assurance in radiopharmaceutical therapy across Canada. Attendees will gain insights into the collaborative processes and innovative strategies employed to formulate these guidelines, which are crucial for the effective management and delivery of radiopharmaceutical treatments.
MaRS Auditorium
12:15 pm
Lunch sponsored by Telix Pharmaceuticals
MaRS Concourse
1:10 pm
Session Chair: Dr. Aruz Mesci
Shaping a rural isotope ecosystem
Jessica Linthorne
Summary: Jessica Linthorne speaks about the opportunities for clean energy communities to work towards a regional isotope ecosystem, highlighting innovative initiatives like the Southwestern Ontario Isotope Coalition and its network of regional partners exploring new avenues for economic development and collaboration.
Mental Health & Medical isotopes
Dr. Neil Vasdev
Summary: Dr. Vasdev examines the intersection of mental health and medical isotopes, highlighting how advancements in radiopharmaceuticals are opening new frontiers in patient care, diagnosis, drug development, and clinical research.
A multidisciplinary collaborative model for the care of cancer patients with radiotheranostics
Dr. David Kirsch
Summary: Cancer is a complex disease. Optimal patient care results from an integrated multidisciplinary team with complimentary skills and expertise. By applying this approach to the rapidly emerging field of radiotheranostics through collaboration across multiple disciplines, we can optimize patient care, develop practice-changing treatment approaches, and create novel educational pathways to build the multidisciplinary workforce of the future.
Theranostics principles of imaging: Bringing better treatments to patients
Carlos Uribe
Comprehensive Solutions for the Rapidly Advancing Field of Radiotheranostics
Sergio Calvo
Summary: Through innovative solutions, industry leaders like GE Healthcare are partnering with healthcare customers to advance radiotheranostics through groundbreaking technology, intelligent devices, and care solutions. Utilizing better tools helps to enable superior patient care and access, which contributes to a healthier future and pushes the boundaries of cancer care.
MaRS Auditorium
2:25 pm
Session Chair: Dr. Jonathan Romsa
Beyond NET and prostate cancer
Dr. Freddy Escorcia
Summary: Dr. Escorcia will present novel therenostics using emerging targets and tumor types that are in current clinical trials, and share his group’s HCC-focused approach toward systematizing target and biomolecule discovery, conjugate design/engineering and rigorous validation pipeline with translational intent.
Novel combined modality opportunities
Dr. Kate Vallis
Summary:. Recent progress in the use of RPT in combination with other modalities will be reviewed and the multimodal clinical studies designed to improve outcome and counter resistance will be discussed. Emerging preclinical and clinical data that support the combination of RPT with immunotherapy, DNA damage response inhibitors and external beam radiotherapy will be highlighted. Opportunities and challenges to the adoption of these approaches will be considered.
MaRS Auditorium
3:15 pm
Coffee & networking
MaRS Concourse
3:35 pm
Pat Dalzell (Session Chair), Rachel Pickering, Patrick Reid, Laura Van Soelen
Summary: With the invaluable expertise of leaders in the nuclear supply chain in Canada, this session addresses the techniques to overcome supply chain challenges and promote resiliency to expand the Canadian medical isotope market.
MaRS Auditorium
4:05 pm
Lise Taylor (Session Chair), Dr. François Bénard, Dr. Jonathan Boekhoud, Dr. Mary Gospodarowicz, Kathryn Hayashi, Dr. Bradley Wouters
Summary: A panel of industry and healthcare experts discuss Canada’s future in radiopharmaceutical innovation. The panel will explore strategic ways to drive innovation, expand access to cutting-edge treatments, and maintain Canada’s leadership in the global isotope landscape.
MaRS Auditorium